• English
    • español
    • português (Brasil)
  • English 
    • English
    • español
    • português (Brasil)
  • Login
View Item 
  •   COVID-19
  • Resources in English
  • Technical documents and research evidence on COVID-19
  • View Item
  •   COVID-19
  • Resources in English
  • Technical documents and research evidence on COVID-19
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

The Cardiac Toxicity of Chloroquine or Hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-regression Analysis

 
Thumbnail
Date
2020-10-19
Author
Tleyjeh, Imad M. et al.
Metadata
Show full item record
Abstract
Objective: To systematically review the literature and estimate the risk of Chloroquine (CQ) and hydroxychloroquine (HCQ) cardiac toxicity in COVID-19 patients. Methods: We searched multiple data sources including PubMed/MEDLINE, Ovid Embase, Ovid EBM Reviews, Scopus, and Web of Science, and medrxiv.org from November 2019 through May 27, 2020. We included studies that enrolled COVID-19 patients treated with CQ or HCQ, with or without azithromycin and reported on cardiac toxicities. We performed a meta-analysis using the arcsine transformation of the different incidences. Results: A total of 19 studies with a total of 5652 patients were included. The pooled incidence of TdP arrhythmia or VT or cardiac arrest was 3 per 1000, 95% CI (0-21), I2=96%, 18 studies with 3725 patients. Among 13 studies of 4334 patients, the pooled incidence of discontinuation of CQ or HCQ due to prolonged QTc or arrhythmias was 5%, 95% CI (1-11), I2=98%. The pooled incidence of change in QTc from baseline of ≥ 60 ms or QTc ≥ 500 ms was 9%, 95% CI (3-17), I2=97%. Mean/median age, coronary artery disease, hypertension, diabetes, concomitant QT prolonging medications, ICU care, and severity of illness in the study populations explained between-studies heterogeneity. Conclusions: Treatment of COVID-19 patients with CQ or HCQ is associated with a significant risk of drug-induced QT prolongation and relatively higher incidence of TdP/VT/cardiac arrest. Therefore, these agents should not be used routinely in the management of COVID-19 disease. COVID-19 patients who are treated with antimalarials for other indications should be adequately monitored.
URI
https://doi.org/10.1016/j.mayocpiqo.2020.10.005
Collections
  • Technical documents and research evidence on COVID-19

Browse

AllCommunities & CollectionsBy Issue DateAuthorsTitlesCategorySubjectsThis CollectionBy Issue DateAuthorsTitlesCategorySubjects

My Account

LoginRegister

Pan American Health Organization
World Health Organization. Regional Office for the Americas
525 Twenty-third Street, N.W., Washington, D.C. 20037, United States of America

Content Disclaimer (Important notes about the material)

Links

  • WHO International Clinical Trial Registry Platform (ICTRP)
  • WHO Coronavirus disease R&D Blueprint
  • WHO Database of Publications on Coronavirus Disease
  • PAHO Coronavirus Disease
  • PAHO/BIREME Windows of Knowledge COVID-19
  • Evidence aid Coronavirus (COVID-19) resources

  • PAHO Digital Library (IRIS PAHO)
  • Virtual Health Library (VHL)
  • Global Index Medicus (GIM)